Key result
Hydrops predicts ~17-fold higher neonatal mortality in fetal cardiac rhabdomyoma.
Why the study?
Cardiac rhabdomyoma is the most common fetal cardiac tumor and is frequently linked with tuberous sclerosis complex, but pre- and postnatal factors affecting mortality remained to be clarified.
Systematic Review (n=859)
In fetal cardiac rhabdomyoma, hydrops is the strongest predictor of neonatal mortality, while the presence of multiple tumors strongly predicts tuberous sclerosis complex.
Answers are grounded in this paper and cite their sources.
Hydrops warrants heightened fetal surveillance for mortality risk; confirms multiple tumors as TSC predictor.
Purpose Cardiac rhabdomyoma, the most common fetal cardiac tumor, is frequently associated with tuberous sclerosis complex (TSC). This study examined pre‐ and postnatal factors affecting mortality in fetal cardiac rhabdomyoma (FCR) and explored links between TSC and clinical features. Methods A systematic review was conducted in July 2023 using Medline, Web of Science, Embase, and Cochrane Library to identify reported FCR cases. Analyses were performed on two sample groups (A and B). Results Neonatal mortality was significantly associated with hydrops ( p < 0.001), tumor progression ( p < 0.001), fetal heart failure ( p < 0.001), and fetal growth restriction (FGR) ( p = 0.021). Hydrops was the strongest predictor of mortality (Sample A: RR 17.2, p = 0.027; Sample B: RR 12.2, p = 0.006). Among 683 cases, 73% were diagnosed with TSC. Multiple tumors increased the likelihood of TSC (Sample A: RR 4.8, p < 0.0001; Sample B: RR 3, p = 0.015). In postnatal factors, preterm delivery ( p < 0.001), cardiac arrhythmia ( p = 0.001), and heart failure ( p < 0.001) were also linked to mortality. Conclusions Hydrops is the strongest mortality predictor in FCR. Multiple tumors are associated with TSC. In prenatal factors, tumor progression, fetal heart failure, and FGR were associated with increased mortality.
No takes yet. Share an insight, caveat, or question.
Azizinik et al. (2026) conducted a systematic review in Fetal cardiac rhabdomyoma (n=859). Hydrops was evaluated on Neonatal mortality (RR 17.2, p=0.027). Hydrops was the strongest predictor of neonatal mortality in fetal cardiac rhabdomyoma (RR 17.2, p=0.027 in Sample A; RR 12.2, p=0.006 in Sample B).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: